IL325831A - Formulations of rock2 inhibitors for cns disorders - Google Patents
Formulations of rock2 inhibitors for cns disordersInfo
- Publication number
- IL325831A IL325831A IL325831A IL32583126A IL325831A IL 325831 A IL325831 A IL 325831A IL 325831 A IL325831 A IL 325831A IL 32583126 A IL32583126 A IL 32583126A IL 325831 A IL325831 A IL 325831A
- Authority
- IL
- Israel
- Prior art keywords
- formulations
- cns disorders
- rock2 inhibitors
- rock2
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363514042P | 2023-07-17 | 2023-07-17 | |
| PCT/IB2024/056936 WO2025017500A1 (en) | 2023-07-17 | 2024-07-17 | Formulations of rock2 inhibitors for cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325831A true IL325831A (en) | 2026-03-01 |
Family
ID=92302638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325831A IL325831A (en) | 2023-07-17 | 2024-07-17 | Formulations of rock2 inhibitors for cns disorders |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2024294840A1 (en) |
| IL (1) | IL325831A (en) |
| WO (1) | WO2025017500A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026053168A1 (en) * | 2024-09-06 | 2026-03-12 | Graviton Bioscience Bv | Amorphous forms of a rock2 inhibitor and formulations thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4201178C2 (en) | 1992-01-17 | 1995-12-07 | Alfatec Pharma Gmbh | Process for the production of soft gelatin capsules by a dropping process |
| NL1009107C2 (en) | 1997-11-12 | 1999-06-15 | Banner Pharmacaps Inc | Extrusion device for forming multi layer gelatine films used to form soft gel capsules - contains two height adjustable gate valves covering nozzle opening to control thickness of the individual extruded gelatine film layers |
| JP2002529398A (en) | 1998-11-11 | 2002-09-10 | バイオプログレス・テクノロジー・インターナショナル・インコーポレイテッド | Capsules for drug delivery systems |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| US10857157B2 (en) * | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| WO2019000682A1 (en) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho-associated protein kinase inhibitor, pharmaceutical composition containing rho-associated protein kinase inhibitor, preparation method and use of the pharmaceutical composition |
| CN110582489B (en) | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho-related protein kinase inhibitors, pharmaceutical compositions containing the same and preparation methods and uses thereof |
| US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
| EA202090306A1 (en) * | 2017-07-21 | 2020-06-25 | Кадмон Корпорейшн, Ллк | INHIBITORS OF RHO-ASSOCIATED CONTAINING SUPERSPIRAL PROTEINKINASE |
| CN112969694B (en) | 2018-11-09 | 2023-06-13 | 北京泰德制药股份有限公司 | Rho-associated protein kinase inhibitors, pharmaceutical compositions containing same and uses thereof |
| BR112021017354A2 (en) | 2019-03-01 | 2021-11-16 | Beijing Tide Pharmaceutical Co Ltd | Method for treating fatty liver disease and/or steatohepatitis |
| CA3144113A1 (en) | 2019-06-25 | 2020-12-30 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating idiopathic pulmonary fibrosis |
| KR20230058466A (en) | 2020-08-31 | 2023-05-03 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Methods for preparing novel RHO-associated protein kinase inhibitors and intermediates in manufacturing methods |
| JP2023539276A (en) * | 2020-08-31 | 2023-09-13 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Salts of RHO-related protein kinase inhibitors, solid forms thereof, methods of preparation thereof and uses thereof |
| KR20240095429A (en) * | 2021-11-16 | 2024-06-25 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Nanocrystal preparation of ROCK2 inhibitor and method for preparing the same |
-
2024
- 2024-07-17 IL IL325831A patent/IL325831A/en unknown
- 2024-07-17 AU AU2024294840A patent/AU2024294840A1/en active Pending
- 2024-07-17 WO PCT/IB2024/056936 patent/WO2025017500A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024294840A1 (en) | 2026-02-26 |
| WO2025017500A1 (en) | 2025-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295364B1 (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders | |
| IL316616A (en) | Inhibitors of rock2 | |
| IL315722A (en) | Piperazine substituted indazole compounds as inhibitors of parg | |
| EP4100403A4 (en) | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders | |
| IL325831A (en) | Formulations of rock2 inhibitors for cns disorders | |
| ZA202212146B (en) | Inhibitors of nek7 kinase | |
| EP4452967A4 (en) | Inhibitors of sars-cov-2 | |
| IL325528A (en) | Use of glycerides for lnp formulations | |
| IL325596A (en) | Pharmaceutical compositions for inhibitors of nek7 kinase | |
| CA3298108A1 (en) | Formulations of rock2 inhibitors for cns disorders | |
| IL325832A (en) | Formulations and uses of rock2 inhibitors for als | |
| IL309182A (en) | Protease inhibitors for the treatment of coronavirus infections | |
| EP4153616A4 (en) | Compositions and methods for treatment of inflammatory disorders | |
| EP4100065A4 (en) | Use of mirna-485 inhibitors for treating tauopathy | |
| IL319571A (en) | R-trihexyphenidyl for treatment of movement disorders | |
| GB202201708D0 (en) | Compositions for oral delivery of biotherapeutics | |
| CA3273444A1 (en) | Inhibitors of rock2 | |
| HK40122640A (en) | Inhibitors of rock2 | |
| HK40076349A (en) | Allogeneic composition for treatment of cns disorders | |
| IL320731A (en) | Compositions and methods for cns diseases | |
| HK40082232A (en) | Compounds and compositions for treating cns disorders | |
| HK40082254A (en) | Compounds and compositions for treating cns disorders | |
| IL317760A (en) | Benzocarbazole derivatives as inhibitors of drp1 | |
| CA3297265A1 (en) | Pharmaceutical compositions for inhibitors of nek7 kinase | |
| GB202203181D0 (en) | Inhibitors of elF4A |